Conatus Pharmaceuticals' (CNAT) Price Target Raised to $26 at SunTrust
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Stifel Raises price Target on Conatus Pharmaceuticals (CNAT) to $7; Reiterates Buy
December 20, 2016 8:59 AM ESTStifel reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), and raised the price target to $7.00 (from $5.00), following the company's announced option, license and collaboration agreement with Novartis for WW emricasan development and commercialization.
Analyst Stephen Willey commented, "We view the Novartis emricasan collaboration as a... More
Conatus Pharmaceuticals (CNAT) Novartis Deal 'Significantlly' De-risks Emricasan - FBR Capital
December 20, 2016 8:39 AM ESTFBR Capital analsyt Vernon Bernardino reiterated an Outperform rating and $16 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) after the company announced that it had entered into an exclusive global development and commercialization agreement with NVS for emricasan in multiple liver diseases, including non-alcoholic steatohepatitis (NASH) and liver cirrhosis (LC).
Bernardino "We... More
Conatus Pharmaceuticals (CNAT) PT Raised to $18 at H.C. Wainwright on Novartis Deal
December 20, 2016 7:28 AM ESTH.C. Wainwright analyst Ed Arce reiterated a Buy rating and raised his price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $18.00 (from $9.00) after the company announced an exclusive global license and collaboration agreement with Novartis covering emricasan, across all indications, either as a single-agent... More
After-Hours Stock Movers 12/19: (CNAT) (IONS) Higher; (NPTN) (SCMP) (REN) Lower (more...)
December 19, 2016 6:02 PM ESTToday's After-Hours Movers:
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) 113.8% HIGHER; entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis (NYSE: NVS), Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with... More
Conatus Pharmaceuticals (CNAT) Surges 150% as Trading Resumes Following Novartis Deal
December 19, 2016 5:03 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) surges 155% as trading resumes following a collaboration and license agreement with Novartis.
... MoreConatus Pharmaceuticals (CNAT) to Resume Trading at 5PM ET
December 19, 2016 4:43 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 5PM ET
... MoreConatus Pharmaceuticals (CNAT), Novartis (NVS) Enter Collaboration and License Agreement for Emricasan
December 19, 2016 4:32 PM ESTConatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis (NYSE: NVS), Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis.
Conatus is eligible to receive significant payments if... More
